Viridian Therapeutics Price To Sales vs. Net Income
For Viridian Therapeutics, market value and book value represent two distinct lenses on the same underlying business. Viridian Therapeutics' market capitalization is 2.76 B. At P/B 4.67, Viridian Therapeutics trades at a significant premium to book value. Enterprise value stands at 2.07 B. Where intrinsic value falls relative to market price and book value helps frame the analytical picture.
Distinguishing between Viridian Therapeutics' value and market price helps frame analytical expectations. By contrast, Viridian Therapeutics market price reflects the level where buyers and sellers transact.
Viridian Therapeutics Net Income vs. Price To Sales Fundamental Analysis
Peer comparison models estimate Viridian Therapeutics's intrinsic positioning within its sector. Viridian Therapeutics lands at #5 in price to sales compared to key competitors. It is rated below average in net income compared to key competitors . Earnings-based multiples benchmark Viridian Therapeutics's market valuation.Viridian Net Income vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Viridian Therapeutics |
| = | 38.92 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much the market values every dollar of the company's sales.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Viridian Therapeutics |
| = | -342.6 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Viridian Net Income Comparison
Viridian Therapeutics is currently under evaluation in net income compared to key competitors.
Viridian Therapeutics Profitability Projections
Viridian Therapeutics's ability to earn and keep profits over time is one of the most direct signs of business quality. The direction and pace of Viridian Therapeutics' profit changes give forward-looking signals for investors.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts. Viridian Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people.
Viridian Profitability Driver Comparison
The key profitability drivers of Viridian Therapeutics determine how much profit the company generates over time. Investors must contend with external shocks that can disrupt Viridian Therapeutics' financial results at any time. Understanding these drivers helps investors separate temporary disruptions from structural changes in Viridian Therapeutics' profits. Track changes in Viridian Therapeutics' profitability drivers to maintain a current view of its investment attractiveness.
Earnings per Share Projection vs Actual
Use Viridian Therapeutics in pair-trading
Pair analysis around Viridian Therapeutics matters because it can turn one security idea into a more market-neutral structure. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Viridian Therapeutics Pair Trading
Viridian Therapeutics Pair Trading Analysis
Tax-loss harvesting on Viridian Therapeutics requires identifying a similar asset for the 30-day wash-sale period. Assets with high correlation to Viridian Therapeutics can serve as substitutes while preserving market exposure. Institutional investors use correlation analysis to build Viridian Therapeutics replacement strategies beyond sector matching. Tax-aware investors benefit from systematic correlation analysis when managing Viridian Therapeutics positions.
Correlation analysis for Viridian Therapeutics reveals which assets move together and which provide hedging benefits. Pairing Viridian Therapeutics with uncorrelated instruments can reduce portfolio volatility without reducing expected returns. Readings above 0.8 indicate strongly correlated pairs with minimal diversification benefit around Viridian Therapeutics. Investors who monitor Viridian Therapeutics correlations can identify regime changes before they impact portfolio risk.
Hedging context for Viridian Therapeutics can be developed through Correlation analysis and pair trading analysis.Use Investing Themes to Complement your Viridian Therapeutics position
At 2.76 Billion in the Biotechnology space, Viridian Therapeutics smaller-cap profile gives investors a structured starting point for building sector-aligned themes. Anchoring a Biotechnology theme around Viridian Therapeutics at 2.76 Billion can be tuned for upside participation or tighter downside control depending on Healthcare outlook.
Did You Try This Idea?
Run Cleaning Thematic Idea Now
Cleaning
Compnanies producing and distributing cleaning products, supplies, and accessories. The Cleaning theme has 42 constituents at this time.
The Cleaning Theme can be deployed as a buy-and-hold allocation or traded actively around individual position volatility.
| View All Next | Launch |